PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) is a neuropeptide originally isolated from the ovine hypothalamus (28) , exhibiting 68% homology with vasoactive intestinal polypeptide (VIP) (1) . It was discovered on the basis of its ability to increase adenylate cyclase activity in the rat pituitary (28) . VIP and PACAP belong to the same superfamily (the glucagon/ secretin superfamily) and act on G protein-coupled receptors with seven conserved transmembrane domains (2, 29, 34) . In the central nervous system, PACAP and VIP have been involved in various biological functions, including neurotransmission, neuroprotection, neuronal growth and differentiation, pain transmission, and hypophysial secretion (2, 11, 27, 29) . In peripheral tissues, PACAP exhibits a variety of biological activities involving activation of adenylate cyclase and protein kinase A (PKA), an increase in intracellular Ca 2ϩ concentration, and/or the activation of phospholipase C and protein kinase C (PKC) (2, 29, 34) . In pancreatic ␤-cells, PACAP appears to be by far the most potent insulinotropic peptide known, stimulating insulin release at 0.1 pmol/l (23, 39) .
PACAP-related peptides also strongly affect cardiac function (4, 10, 35) , but few studies on their effects on cardiac excitability exist. We hypothesized that PACAP peptides modulate cardiac ATP-sensitive K ϩ (K ATP ) channels for three reasons. First, K ATP channels play a fundamental role in cardiac excitability (3) . Second, PACAP peptides are known to induce an endothelium-independent relaxation of the human and porcine coronary artery as well as the pulmonary artery, partly via activation of K ATP channels (6, 7, 21) . Third, the PACAP-related peptide VIP has been detected in intracardiac nerve endings (12) , raising the possibility that PACAP-related peptides may affect both vascular smooth muscle and striated myocytes of the heart. The atrial myocytes were the main focus of our study, because atrial K ATP channels potently modulate the stimulated atrial natriuretic peptide (ANP) secretion (20, 38) , and PACAP peptides are known to affect various endocrine systems (4, 23, 39) . The atrial K ATP channel is also interesting because of its high sensitivity to various K ATP channel modulators (3) .
For these reasons, the goals of this study on primary cultured neonatal rat atrial myocytes were the following: 1) identify and characterize the subtypes of PACAP receptors (2, 14, 16, 27, 29, 34, 36) , 2) identify and characterize a PACAP-stimulated K ATP current with the whole cell patch-clamp technique, and 3) determine whether the signaling pathway involved PKA, PKC, or both.
MATERIALS AND METHODS
Atrial myocyte cultures. Atrial appendage myocytes from 2-to 3-day-old rats were cultured as described previously (3, 20, 24) . Briefly, the atrial appendages were minced, dis-persed enzymatically with 0.2% trypsin (Worthington; Allschwil, Switzerland), and dispersed mechanically by repeated pipetting in Ca 2ϩ -and Mg 2ϩ -free medium. Cells were grown in 10% FCS-containing culture medium, a 1:1 mixture of Dulbecco's modified Eagle's medium, and Ham's F-12 (GIBCO-BRL; Basel, Switzerland) for 2-4 days in a 5% CO 2 incubator. Cultured atrial myocytes were shown to express ANP mRNA by RT-PCR (Fig. 1C) and ANP by immunostaining (20) , with at least 70% of all cells being myocytes on days 2 and 3 of culture. Between 10 and 50% of the myocytes contracted spontaneously at a rate of 0.1-1 Hz, and noncontracting myocytes could be induced to contract by mechanical stimulation, indicating that the myocytes were normally polarized.
Patch-clamp recording of K ATP current. K ATP currents were recorded on culture days 2-4 at room temperature from initially beating atrial myocytes with the use of the whole cell configuration of the patch-clamp technique (3, 13, 20) . Room temperature was chosen to aid the performance of long-term recordings. The cells were observed with an inverted microscope (Diaphot TMD, Nikon; Tokyo, Japan). The currents were recorded by an Axopatch 200B patch-clamp amplifier, digitized by a TL-1 dimethyl amiloride interface, and sampled with the use of a personal computer running pCLAMP software (Axon Instruments). Borosilicate glass patch pipettes were pulled with a BB-CH puller (Mecanex; Nyon, Switzerland) to a resistance of 2-4 M⍀. The standard pipette solution contained (in mmol/l) 121 KCl, 1.5 CaCl 2 , 10 EGTA, 1.3 MgCl 2 , 5 ATP, 10 glucose, 34 KOH, and 10 HEPES, pH 7.45 with KOH. The bathing solution contained (in mmol/l) 5 KCl, 1 CaCl 2 , 1 MgCl 2 , 118 NaCl, 10 glucose, and 10 HEPES, pH 7.5 with NaOH. The osmolality was adjusted with sucrose to 290 mosmol/kg H 2 O. The currents were filtered at 2 kHz and sampled at the frequency of 0.8 kHz.
Whole cell K ATP currents were recorded on initially beating atrial cardiomyocytes during a 10-s voltage ramp from Ϫ80 to ϩ90 mV. A holding potential of Ϫ40 mV and the slow ramp protocol prevented the activation of voltage-dependent channels. The protocol also allowed for the recording of current voltage (I-V) relationships, indicating the typically low inward rectification of the K ATP channels. The EGTA-buffered low Ca 2ϩ concentration in the patch pipette (10.5 nmol/l free Ca 2ϩ ), as calculated by the WinMAX chelator software (version 1, 1995, Stanford University), prevented the activation of Ca 2ϩ -dependent currents. The presence of 5 mmol/l ATP in the pipette prevented the spontaneous activation of K ATP current even during prolonged recordings (30-50 min), but did not prevent the activation by K ATP channel openers (3). Recordings with cell membranes that were stretched by drifting patch pipettes were discarded. The initial leak current was subtracted. The K ATP current amplitude was measured at ϩ50 mV and plotted as a function of time of whole cell recording or expressed as current density (pA/pF) to calculate mean values. The mean membrane capacitance of atrial cardiomyocytes was 13.0 Ϯ 0.4 (SE) pF (n ϭ 134). The K ATP current was compared, whenever possible, with the maximal current activated by 100 mol/l diazoxide on the same cell. The membrane hyperpolarization triggered by the activation of the K ATP current was measured in current clamp mode at 0 pA current. Inhibition by Ͻ1 mol/l glyburide further identified the activated K ϩ current as a K ATP current, because concentrations Ն1 mol/l are required to significantly modulate voltage-dependent channel activity.
Chemicals and drugs. EGTA, ATP, glyburide, diazoxide, 8-(4-chlorophenyl-thio)-cAMP (8-CPT-cAMP) were all purchased from Sigma (St. Louis, MO). 8-CPT-cAMP was dissolved in water, whereas glyburide and diazoxide were dissolved in DMSO at the stock concentration of 10 and 100 mmol/l, respectively. H-89 dihydrochloride (H 89 ) and 1-oleoyl-2-acetyl-sn-glycerol (OAG) were purchased from Calbiochem (La Jolla, CA) and dissolved in DMSO at the stock concentration of 1 and 50 mmol/l, respectively. The PKC inhibitor (PKC-I) peptide (19-31) was purchased from Upstate Biotechnology (Lake Placid, NY) and added to the pipette solution at 50 mol/l. VIP, PACAP-27, and PACAP-38 were purchased from Novabiochem (Laufelfingen, Switzerland) and dissolved in 5% ethanol at the stock concentration of 200, 20, and 20 mol/l, respectively. The two molecular forms of PACAP occur in the brain as well as in peripheral tissues (22, 31) . Because PACAP-38 is the predominant form (90%) in tissues (2), most experiments presented here used PACAP-38.
cAMP assays. Atrial myocytes were cultured for 3-4 days in 24-well culture plates at a density of 250,000 cells/well, equilibrated for 80 min in an extracellular HEPES buffer (see the description above) at 37°C, and stimulated for 40 min in the absence of phosphodiesterase inhibitors with PACAP-38, PACAP-27, or VIP at concentrations indicated in Fig. 1 . Cells were extracted with 65% ethanol, and the samples were frozen at Ϫ30°C, pending radioimmunoassay with the use of a kit (model RPA509, Amersham; Buckinghamshire, UK). On the day of the assay, the samples were evaporated at 65°C under a stream of nitrogen, reconstituted in 500 l assay buffer, and assayed in each tube by using a sample volume of 50 l and 25 l (2,500-3,000 counts/min) of iodinated tracer and 25 l of diluted antibody. Standard curves were similar to manufacturer specifications, with a mean correlation coefficient of 0.958 Ϯ 0.016 (n ϭ 4 assay series).
RT-PCR analysis of PACAP receptors. The nomenclature follows that of Ref. 14. The three cloned PACAP/VIP receptors (2, 26, 29, 34) are called PAC 1 , showing a 1,000-fold greater affinity for PACAPs than VIP (16) , and VPAC 1 and VPAC 2 , showing similar binding properties for PACAPs and VIP (19, 26) . Eight splice variants of PAC 1 have been reported (2, 29) . VPAC 2 is broadly distributed throughout the peripheral tissues, including the pancreas and skeletal muscle, whereas all three PACAP receptor types are found together only in heart, brain, and adipose tissue (2, 14, 27, 36) . Atrium alone was not examined before.
Total RNA from 2-day-old cultured neonatal atrial appendage myocytes, or from 4-day-old atrial appendage or ventricular tissue, was extracted by TRIzol Reagent (GIBCO-BRL) and subjected to RQ1 DNase (Promega; Wallisellen, Switzerland) digestion. Total RNA (1 g) was used for RT experiments. cDNAs were synthesized with random hexaprimers (Boehringer) and Superscript II RT (200 units; GIBCO-BRL) at 37°C during 2 h. PCR was carried out in a HYBAID personal cycler in a final volume of 50 l containing 1 l of the RT reaction, 1 unit of Taq polymerase (Appligene Oncor), 1.5 mmol/l MgCl 2 , 250 mol/l of each dNTP, and 20 pmol of each primer. The primers used for detecting PAC1 were the following: forward, 5Ј-CTTGTACAGAAGCTGCAGTC-3Ј (nucleotide position 987-1006); and reverse, 5Ј-GGTGCTT-GAAGTCCATAG-3Ј (position 1288-1266). The spanned region covers the splice sites for a short form (301 bp) and two long forms (Hip, 385 bp; Hop-1, 385 bp; and Hop-2, 382 bp). For VPAC 1 , the primers were the following: forward, 5Ј-GCCCCCATCCTCCTCTCCATC-3Ј (position 959-978); and reverse: 5Ј-TCCGCCTGCACCTCACCATTG-3Ј (position 1258-1236, product size 298 bp). For VPAC 2 , the primers were the following: forward, 5Ј-GTCAACTTTGCCCTCT-TCATCA-3Ј (position 944-966); and reverse, 5Ј-GCCTCTC-CACCTTCTTTTCAG-3Ј (position 1241-1220, product size 297 bp). The PCR conditions were 40 cycles at 95°C/30 s, 60°C/30 s, and 72°C/30 s. The PCR products were separated by electrophoresis on a 2.5% agarose gel and visualized with ethidium bromide under ultraviolet fluorescence. RT was omitted in controls.
Statistical analysis. cAMP assay and electrophysiology results are presented as means Ϯ SE and analyzed for statistically significant differences by ANOVA and Duncan's multiple-range test from the SAS Institute (Cary, NC).
RESULTS

Cultured atrial cells contain functional PACAP re-
ceptors. PACAP-38 (0.01-100 nmol/l) dose dependently stimulates the production of cAMP in atrial appendage cultures (Fig. 1A) , with an EC 50 ϭ 0.28 nmol/l (r ϭ 0.92, P Ͻ 0.02). A similar EC 50 (0.49 nmol/l) was established in a repeat experiment (r ϭ 0.94, P Ͻ 0.02). PACAP-27 at 10-100 nmol/l has the same effects as PACAP-38 (Fig. 1B ), but the effects of 100 nmol/l VIP on cAMP are 1.9 times (Fig. 1B) to 3.5 times less (repeat experiment, not shown, P Ͻ 0.05). The EC 50 for VIP cannot be accurately estimated but is between 1 and 10 nmol/l.
Characterization of PACAP receptors by RT-PCR clearly shows the presence of mRNA coding for at least two isoforms of PAC 1 and for VPAC 1 and VPAC 2 in atrial appendage cell culture (Fig. 1C, right) . The expected sizes of the PCR products correspond to the position of the bands in the gel. A similar expression pattern is observed for mRNA extracts of atrial appendages (Fig. 1C, left) and ventricular tissue (Fig. 1C,  middle) . Tissue and culture extracts show a strong band for both ␤-actin and atrial natriuretic factor. Controls without RT and with ␤-actin primers are negative.
PACAP-38 activates a K ATP current in atrial appendage myocytes. No spontaneous activation of the K ATP channel occurs in the presence of 5 mmol/l ATP in the patch pipette. However, the extracellular application of 100 nmol/l PACAP-38 strongly activates the K ATP current (Fig. 2, A and B, trace b) , although there is a variable delay between drug application and increase in current. The current shows a weak inward-rectifying I-V relationship with a reversal potential near Ϫ80 mV ( Fig. 2A) . Diazoxide can stimulate this current further (Fig. 2, A and B, trace c) . In 44 myocytes, the effect of PACAP-38 is dose dependent, with an EC 50 close to 3 nmol/l and a maximal effect at 10 nmol/l (Fig.  2C ). The maximal current density reached with 10 nmol/l PACAP-38 (91 Ϯ 15 pA/pF, n ϭ 18) represents 91 Ϯ 15% of the current density reached in 22 myocytes with 100 mol/l diazoxide. A better estimate of the relative effect of PACAP-38 is obtained in six experiments, where both drugs could be tested on the same cell, and where diazoxide increases the PACAP-38-induced current by 78% (P Ͻ 0.05). This indicates that PACAP-38 does not elicit maximal effects on the K ATP current. With only 2 mmol/l ATP in the pipette solution, 1 nmol/l PACAP activates a K ATP current of 85 Ϯ 35 pA/pF (n ϭ 4) compared with 26 Ϯ 15 pA/pF (n ϭ 9) with 5 mmol/l ATP, suggesting that low internal ATP increases the effectiveness of PACAP-38.
Permeant analog of cAMP activates the atrial K ATP current. To determine whether cAMP was involved in the activation of atrial K ATP current by PACAP-38, we studied the effects of a permeant analog of cAMP, 8-CPT-cAMP. The bath application of 100 mol/l 8-CPT-cAMP activates a K ATP current (Fig. 3, A and B,  trace b) , which can be further activated by 100 mol/l diazoxide (Fig. 3, A and B, trace c) . The 8-CPT-cAMP (100 M) activates a mean maximal current of 31.8 Ϯ 6.2 pA/pF (n ϭ 16) compared with the mean maximal current of 100.3 Ϯ 10.3 pA/pF (n ϭ 22) activated by 100 mol/l diazoxide. However, the 8-CPT-cAMP-activated K ATP current induces a near-maximal membrane polarization, reaching Ϫ63 Ϯ 4 mV (n ϭ 16) compared with Ϫ69 Ϯ 2 mV (n ϭ 22) for 100 mol/l diazoxide and Ϫ68 Ϯ 2 mV (n ϭ 18) for 10 nmol/l PACAP-38. Considering the eight experiments where diazoxide and 8-CPT-cAMP could be applied on the same cell, the 8-CPT-cAMP-induced current is 30 Ϯ 11% of the maximal diazoxide-induced current. 
Effects of the PKA inhibitor H 89 on the PACAPactivated atrial K ATP current.
The PKA inhibitor H 89 was used to block the effects of cAMP because it is described as a rather selective inhibitor of PKA, with inhibitory constant (K i ) ϭ 48 nmol/l, compared with PKC, where K i ϭ 31.7 mol/l (8). Used externally at 1 mol/l, H 89 strongly inhibits the diazoxide-activated K ATP current to 7.5 Ϯ 1.9 pA/pF (n ϭ 3) from a control amplitude of 100.3 Ϯ 10.3 pA/pF (n ϭ 22). At 0.5 mol/l, H 89 much more strongly reduces PACAP-38 than the diazoxide-induced current (Fig. 4, A and B) . The diazoxide-induced K ATP current is reduced to 30.5 Ϯ 25.2 pA/pF (n ϭ 6) (Fig. 4C, open bar) , corresponding to 30.4% of the control current. This concentration of H 89 totally inhibits the K ATP current induced by 100 mol/l 8-CPT-cAMP (Fig. 3C ) and reduces the 10 nmol/l PACAP-38-induced K ATP current to 5.0 Ϯ 2.7 pA/pF (n ϭ 5) (Fig. 4C, hatched bar) , corresponding to 8 Ϯ 4% (n ϭ 5) of the current induced by diazoxide on the same cell. Thus, although H 89 exerts a probably nonspecific partial inhibition of the K ATP current, it strongly affects the 8-CPT-cAMP-and PACAP-38-induced currents. Figure 4, A and B (33) . With 50 mol/l PKC-I in the patch pipette and after 10 min of whole cell recording to allow the diffusion of the inhibitor into the cytoplasm, 10 nmol/l PACAP induces a significantly reduced K ATP current of 33.2 Ϯ 17.8 pA/pF (n ϭ 6) (Fig. 5, A and B, trace b) . This result compares with 91 Ϯ 15 pA/pF (n ϭ 18) in the absence of PKC-I (Fig.  5C , hatched bars, P Ͻ 0.05). The presence of PKC-I does not affect the cAMP-activated K ATP current (Fig.  5C, solid bars) , whereas the OAG-activated K ATP current amplitude is reduced from 50.9 Ϯ 16.5 pA/pF (n ϭ 7) in control condition to 15.3 Ϯ 10.7 pA/pF (n ϭ 5) in the presence of 50 M of PKC-I (not shown).
Interestingly, VIP is able to elicit a K ATP current in the presence of PKC-I, as shown in the example of Fig.  5, A and B (trace c) , and statistically in Fig. 5C (open columns). The responses to 10 nmol/l VIP are variable, however, because some myocytes fail to respond to VIP, whereas they respond to 10 nmol/l PACAP-38 and 10 mol/l diazoxide (example, Fig. 6 ).
DISCUSSION
In this study we show the following: 1) PACAPrelated peptides potently stimulate cAMP production in primary cultured atrial myocytes, with an order of potency PACAP-38 ϭ PACAP-27 Ͼ VIP; 2) atrial myocytes in culture have at least two splice variants of PAC 1 and also contain VPAC 1 and VPAC 2 ; 3) PACAP-38 activates an atrial myocyte K ATP current in a dosedependent manner, PACAP-38 being significantly more potent than VIP; and 4) pharmacological blockade of the PKA or PKC pathway attenuates the K ATP current response to PACAP-38.
Multiple types of PACAP receptors in atrial myocytes. Functional and molecular evidence supports the notion that atrial myocytes contain multiple types of PACAP receptors. First, cAMP responses are much more pronounced for PACAP-38 than VIP (Fig. 1B) , as also shown by others on cultured cardiocytes (4), suggesting the presence of PAC 1 (ϭ PVR 1 ) in combination with VPAC 1 (ϭ PVR 2 ) and/or VPAC 2 (ϭ PVR 3 ) (compare with Table 1 in Ref. 29) . Second, PACAP-38 much more potently and consistently stimulates the atrial K ATP current than VIP (Fig. 5 and 6 ), either because it more potently stimulates PKA or because it stimulates both PKA and PKC. In either case, one would infer from Rawlings and Hezareh (29) that PACAP-38 stimulates PAC 1 in combination with VPAC 1 and/or VPAC 2 . Third, RT-PCR indicates the existence of three main types of PACAP-38 receptors in atrial myocytes, PAC 1 , VPAC 1 , and VPAC 2 , with at least two splice forms for PAC 1 .
The PCR product of 301 bp corresponds to the short form of PAC 1 (34) , whereas the 385-bp product contains an 84-bp insert represented by Hip or Hop-1. It cannot be distinguished here from a 382-bp insert corresponding to Hop-2. It is known that Hip strongly diminishes the cAMP responses (34) , and as Fig. 1A shows that cAMP is strongly activated by PACAP-38 (EC 50 0.28 nmol/l), this suggests that the insert most likely is not Hip. Further experiments, such as Southern blot with specific probes for each form, would be needed to confirm this. The PAC 1 -Hip-Hop forms are not detectable (Fig. 1C) . These results on atrial myocytes differ from those of Braas et al. (5), who found that PAC 1 receptors in cardiac ganglia mostly do not contain an insert in the third cytoplasmic loop as shown here.
The RT-PCR results of Fig. 1C also show that the distribution of different PACAP receptors is quite similar in atrial tissue, ventricular tissue, and primary atrial cell culture. Although Northern blots fail to demonstrate cardiac VPAC receptors (18, 19) , the presence of the three main PACAP receptor types in the whole heart has previously been shown by RNAse protection assay (36) . The great majority of cells in the atrial cell cultures are myocytes (20) , but it is not possible to conclude that all myocytes contain all isoforms shown. Indeed, the heterogeneity in responsiveness of the K ATP current to VIP (Fig. 5 and 6 ) would suggest that some myocytes do not contain VPAC 1 and VPAC 2 . Single cell RT-PCR, as shown by Rawlings and Heza- PACAP-38 activates the atrial K ATP current via PKA and PKC. Consistent with the presence of multiple PACAP receptor types, PACAP-38 potently and dose dependently increases the K ATP current in atrial myocytes. Indeed, the results strongly suggest the involvement of both the PKA and PKC signaling pathways.
The involvement of PKA is indicated by the inhibition by H 89 of the K ATP current induced by 10 nmol/l PACAP-38 (Fig. 4) . This inhibition is total for stimulation by 8-CPT-cAMP, as expected. However, H 89 also partially inhibits the stimulation of the K ATP current by diazoxide, either because of a basal tone of PKA, or because diazoxide may boost cAMP via inhibition of phosphodiesterase, or because of unknown nonspecific effects. Because the inhibition of stimulation by PACAP-38 is far greater than the inhibition of stimulation by diazoxide (Fig. 4C) , it is still possible to conclude that H 89 exerts a specific inhibition of the PACAP-38-stimulated PKA pathway. This result is supported by the strong stimulation by PACAP-38 of cAMP (Fig. 1A) and by the significant stimulation of the atrial K ATP current by 8-CPT-cAMP (Fig. 3C) .
The involvement of the PKC pathway is indicated by the strong inhibition, by cell dialysis with the PKC-I peptide, of the K ATP current induced by 10 nmol/l PACAP-38 (Fig. 5) or by OAG (see RESULTS). This result is supported by another study showing that stimulation of PKC activates ventricular K ATP channels (25) . Interestingly, the K ATP current induced by VIP is not affected by PKC-I, suggesting that a putative stimulation of PKC by VPAC 2 (2, 18) is unlikely in atrial myocytes. It is also noted that stimulation by 8-CPT-cAMP is not affected by PKC-I, as expected.
The relative contribution of the PKA and PKC pathways to the total response of the K ATP current to PACAP-38 cannot easily be inferred. The large inhibitory effect of H 89 in Fig. 4 is partly nonspecific (see above) and cannot be attributed to inhibition of PKA alone. From Fig. 4 and 5, we estimate that one-third of the inhibitory effect is attributable to PKA and twothirds are due to PKC. Such double signaling by PACAP-38 through PKA and PKC is not unprecedented, because it has also been observed for PACAP modulation of the L-type calcium channel in vascular smooth muscle (9) . It is suggested that the stimulation by PKA and PKC would be even more pronounced at 37°C and in intact cells, because the enzymatic activity would be greater at 37°C and second messengers would not be diluted by the patch pipette.
Possible roles of PACAP-related peptides in cardiac function. Recent studies (5, 15) show that PACAPrelated peptides are contained in nervous structures surrounding the heart, in particular in cardiac ganglia and nerve fibers, and may modulate cardiac output via stimulation of the parasympathetic system. The results of our study show that atrial myocytes could also be a target of PACAP-containing fibers surrounding the cardiac myocytes (5) . The activation of the atrial K ATP current by PACAP-38 released from nerve fibers would be expected to cause a shortening of the action potential, a reduction of calcium influx, and a reduction of atrial contraction. By analogy, the demonstration of PACAP receptors in ventricular tissue (Fig. 1C) suggests that PACAP-38 may reduce the ventricular contraction, thus overall causing a reduction in cardiac output. These primary cardiac effects of PACAP-related peptides are probably overshadowed in vivo by their vasodilation actions on the microcirculation and by the reflex activation of the cardiac sympathetic outflow (9, 37) .
In addition to modulating cardiac pumping, PACAPrelated peptides may also modulate cardiac secretion of ANP. PACAP-38 stimulates cAMP accumulation and ANP secretion from cultured cardiomyocytes (4). Because the cardiomyocytes in that study were derived mostly from ventricular tissue, and ventricular myocytes release ANP in response to cAMP (30) , some of the action may be attributed to activation of the cAMP pathway. A significant response is probably also mediated by activation of PKC (4) . In contrast, in atrial myocytes, cAMP mostly inhibits or has no effect on ANP secretion (32) , and activation of K ATP channels by diazoxide inhibits the stimulated ANP secretion in hearts (38) and in atrial myocyte culture (20) . Future experiments should show whether PACAP-38 inhibits or stimulates ANP secretion from atrial tissue or cells.
In conclusion, we show that PACAP-38 potently activates a K ATP current in atrial myocytes. Multiple PACAP receptors and both PKA and PKC pathways are implicated in this response. Together with other studies, the results imply that PACAP-38 would reduce cardiac output, but the initiating stimulus for PACAP release from cardiac nerve fibers is still unknown.
